{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:03:38Z","timestamp":1790269418287,"version":"4.1.0"},"reference-count":155,"publisher":"Elsevier","isbn-type":[{"value":"9780443472169","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.irn.2026.01.002","type":"book-chapter","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:14:49Z","timestamp":1770120889000},"page":"145-174","source":"Crossref","is-referenced-by-count":0,"title":["Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer\u2019s disease"],"prefix":"10.1016","author":[{"given":"Trishna","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awanish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7319","key":"10.1016\/bs.irn.2026.01.002_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A map of human genome variation from population-scale sequencing","volume":"467","author":"Abecasis","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nrd3842-c1","article-title":"Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer\u2019s disease","volume":"12","author":"Aisen","year":"2013","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.irn.2026.01.002_bib3","doi-asserted-by":"crossref","unstructured":"Anderson, R.J.Fi. N. (2022). Can probiotics mitigate age-related neuroinflammation leading to improved cognitive outcomes? 9, 1012076.","DOI":"10.3389\/fnut.2022.1012076"},{"key":"10.1016\/bs.irn.2026.01.002_bib4","doi-asserted-by":"crossref","unstructured":"Andrade-Guerrero, J.,\u00a0et al. (2023).\u00a0Alzheimer\u2019s disease: An updated overview of its genetics. 2023. 24(4), 3754.","DOI":"10.3390\/ijms24043754"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib5","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2026.01.002_bib6","doi-asserted-by":"crossref","unstructured":"Ashton, N. J., et al. (2015).\u00a0Blood protein predictors of brain amyloid for enrichment in clinical trials? 1(1), 48\u201360.","DOI":"10.1016\/j.dadm.2014.11.005"},{"issue":"12","key":"10.1016\/bs.irn.2026.01.002_bib7","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib8","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathologica"},{"issue":"7571","key":"10.1016\/bs.irn.2026.01.002_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib11","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1016\/bs.irn.2026.01.002_bib13","doi-asserted-by":"crossref","unstructured":"Beatriz, M., et al. (2021).\u00a0Exosomes: Innocent bystanders or critical culprits in neurodegenerative diseases. 9, 635104.","DOI":"10.3389\/fcell.2021.635104"},{"issue":"12","key":"10.1016\/bs.irn.2026.01.002_bib14","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.pneurobio.2011.09.011","article-title":"The role of genetics for biomarker development in neurodegeneration","volume":"95","author":"Bertram","year":"2011","journal-title":"Progress in Neurobiology"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41582-021-00549-x","article-title":"Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus","volume":"17","author":"Bettcher","year":"2021","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.irn.2026.01.002_bib17","doi-asserted-by":"crossref","unstructured":"Bowman, G. L., et al. (2018). Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. 14(12), 1640\u20131650.","DOI":"10.1016\/j.jalz.2018.06.2857"},{"issue":"263","key":"10.1016\/bs.irn.2026.01.002_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009759","article-title":"The gut microbiota influences blood-brain barrier permeability in mice","volume":"6","author":"Braniste","year":"2014","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.irn.2026.01.002_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0074-7742(07)82011-3","article-title":"Systemic and acquired immune responses in Alzheimer\u2019s disease","volume":"82","author":"Britschgi","year":"2007","journal-title":"International Review of Neurobiology"},{"key":"10.1016\/bs.irn.2026.01.002_bib20","doi-asserted-by":"crossref","unstructured":"Brum, W. S., et al.\u00a0(2023). A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. 3(9), p. 1079\u20131090.","DOI":"10.1038\/s43587-023-00471-5"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0197-4580(01)00246-9","article-title":"Identification of CD40 ligand in Alzheimer\u2019s disease and in animal models of Alzheimer\u2019s disease and brain injury","volume":"23","author":"Calingasan","year":"2002","journal-title":"Neurobiology of Aging"},{"issue":"6","key":"10.1016\/bs.irn.2026.01.002_bib22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/alz.12447","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib24","first-page":"84","article-title":"Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer\u2019s disease by color-coded bead technology","volume":"4","author":"Choi","year":"2008","journal-title":"Journal of Clinical Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/acschemneuro.8b00457","article-title":"Pathological changes of Tau related to Alzheimer\u2019s disease","volume":"10","author":"Chu","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"9","key":"10.1016\/bs.irn.2026.01.002_bib27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/s41590-021-00994-2","article-title":"Immune cell compartmentalization for brain surveillance and protection","volume":"22","author":"Croese","year":"2021","journal-title":"Nature Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","article-title":"Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations","volume":"1","author":"Cullen","year":"2021","journal-title":"Nature Aging"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib29","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nature Communications"},{"issue":"7323","key":"10.1016\/bs.irn.2026.01.002_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nature09513","article-title":"Pericytes are required for blood-brain barrier integrity during embryogenesis","volume":"468","author":"Daneman","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/bs.irn.2026.01.002_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005096","article-title":"Knocking on closed doors: Host interferons dynamically regulate blood-brain barrier function during viral infections of the central nervous system","volume":"11","author":"Daniels","year":"2015","journal-title":"PLoS Pathogens"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer\u2019s disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"key":"10.1016\/bs.irn.2026.01.002_bib33","doi-asserted-by":"crossref","unstructured":"Delaby, C.,\u00a0Hirtz,\u00a0C.\u00a0&\u00a0Lehmann,\u00a0S. J. R. N. (2023). Overview of the blood biomarkers in Alzheimer\u2019s disease: Promises and challenges. 179(3), p. 161\u2013172.","DOI":"10.1016\/j.neurol.2022.09.003"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12035-021-02612-6","article-title":"Recent advances in molecular pathways and therapeutic implications targeting mitochondrial dysfunction for Alzheimer\u2019s disease","volume":"59","author":"Dhapola","year":"2022","journal-title":"Molecular Neurobiology"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib35","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00415-022-11480-6","article-title":"Neurofilament light chain: A promising diagnostic biomarker for functional motor disorders","volume":"270","author":"Dinoto","year":"2023","journal-title":"Journal of Neurology"},{"issue":"15","key":"10.1016\/bs.irn.2026.01.002_bib36","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","article-title":"Total A\u03b2(42)\/A\u03b2(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis","volume":"94","author":"Doecke","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2026.01.002_bib37","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nn.4030","article-title":"Host microbiota constantly control maturation and function of microglia in the CNS","volume":"18","author":"Erny","year":"2015","journal-title":"Nature Neuroscience"},{"issue":"7","key":"10.1016\/bs.irn.2026.01.002_bib38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2026.01.002_bib39","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1084\/jem.185.12.2171","article-title":"Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes","volume":"185","author":"Forssmann","year":"1997","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.irn.2026.01.002_bib40","doi-asserted-by":"crossref","unstructured":"Frank, B.,\u00a0et al.\u00a0(2022). Plasma p-tau181 shows stronger network association to Alzheimer\u2019s disease dementia than neurofilament light and total tau.\u00a018(8), 1523\u20131536.","DOI":"10.1002\/alz.12508"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/alzrt164","article-title":"Biomarkers for Alzheimer\u2019s disease in plasma, serum and blood - conceptual and practical problems","volume":"5","author":"Galasko","year":"2013","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1016\/bs.irn.2026.01.002_bib42","unstructured":"Gauthier, S., Webster, C., Servaes, S., Morais, J.A. & Rosa-Neto, P. (2022).\u00a0P. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. Alzheimer\u2019s Disease International."},{"key":"10.1016\/bs.irn.2026.01.002_bib43","doi-asserted-by":"crossref","unstructured":"Giacomucci, G., et al.\u00a0(2022). Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment. 269(8), p. 4270\u20134280.","DOI":"10.1007\/s00415-022-11055-5"},{"key":"10.1016\/bs.irn.2026.01.002_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","article-title":"Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study","volume":"3","author":"Gissl\u00e9n","year":"2016","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/pmic.201500396","article-title":"Integrative methods for analyzing big data in precision medicine","volume":"16","author":"Gligorijevi\u0107","year":"2016","journal-title":"Proteomics"},{"issue":"9","key":"10.1016\/bs.irn.2026.01.002_bib46","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.4103\/1673-5374.335163","article-title":"Urolithin a alleviates blood-brain barrier disruption and attenuates neuronal apoptosis following traumatic brain injury in mice","volume":"17","author":"Gong","year":"2022","journal-title":"Neural Regeneration Research"},{"issue":"8","key":"10.1016\/bs.irn.2026.01.002_bib47","first-page":"1757","article-title":"Alzheimer\u2019s disease with sleep insufficiency: A cross-sectional study on correlations among clinical characteristics, orexin, its receptors, and the blood-brain barrier","volume":"18","author":"Guo","year":"2023","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/bs.irn.2026.01.002_bib48","doi-asserted-by":"crossref","unstructured":"Guo, X., et al. (2021). OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP\/PS1 transgenic mice. 12(21), p. 3985\u20133993.","DOI":"10.1021\/acschemneuro.1c00209"},{"key":"10.1016\/bs.irn.2026.01.002_bib49","doi-asserted-by":"crossref","unstructured":"Hampel, H., et al.\u00a0(2017). A precision medicine initiative for Alzheimer\u2019s disease: The road ahead to biomarker-guided integrative disease modeling. 20(2), p. 107\u2013118.","DOI":"10.1080\/13697137.2017.1287866"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nature Reviews Neurology"},{"issue":"18","key":"10.1016\/bs.irn.2026.01.002_bib51","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib52","first-page":"243","article-title":"Precision medicine - the golden gate for detection, treatment and prevention of Alzheimer\u2019s disease","volume":"3","author":"Hampel","year":"2016","journal-title":"Journal of Prevention of Alzheimer\u2019s Disease"},{"key":"10.1016\/bs.irn.2026.01.002_bib53","unstructured":"Hampel, H., et al. (2016b). Precision medicine-the golden gate for detection, treatment and prevention of Alzheimer\u2019s disease. 3(4), p. 243."},{"issue":"7","key":"10.1016\/bs.irn.2026.01.002_bib54","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jalz.2012.05.2116","article-title":"Development of biomarkers to chart all Alzheimer\u2019s disease stages: The royal road to cutting the therapeutic Gordian Knot","volume":"8","author":"Hampel","year":"2012","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"6","key":"10.1016\/bs.irn.2026.01.002_bib56","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/bs.irn.2026.01.002_bib57","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","article-title":"The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: A review","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"key":"10.1016\/bs.irn.2026.01.002_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.212770","article-title":"Bioengineered microglia-targeted exosomes facilitate A\u03b2 clearance via enhancing activity of microglial lysosome for promoting cognitive recovery in Alzheimer\u2019s disease","volume":"136","author":"Hao","year":"2022","journal-title":"Biomaterials Advances"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib59","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","article-title":"Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia","volume":"91","author":"Heller","year":"2020","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2026.01.002_bib60","doi-asserted-by":"crossref","unstructured":"Henriksen, K., et al. (2014a).\u00a0The future of blood-based biomarkers for Alzheimer\u2019s disease. 10(1), p. 115\u2013131.","DOI":"10.1016\/j.jalz.2013.01.013"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","article-title":"The future of blood-based biomarkers for Alzheimer\u2019s disease","volume":"10","author":"Henriksen","year":"2014","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","article-title":"Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease","volume":"43","author":"Hollingworth","year":"2011","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1016\/bs.irn.2026.01.002_bib63","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.nbt.2012.03.004","article-title":"A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory","volume":"29","author":"Hood","year":"2012","journal-title":"New Biotechnology"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/brain\/awaa373","article-title":"CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease","volume":"144","author":"Horie","year":"2021","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2026.01.002_bib65","doi-asserted-by":"crossref","unstructured":"Huang, S.,\u00a0Wang,\u00a0Y.-J., &\u00a0Guo,\u00a0J. J. Nb. (2022).\u00a0Biofluid biomarkers of Alzheimer\u2019s disease: Progress, problems, and perspectives. 38(6), p. 677\u2013691.","DOI":"10.1007\/s12264-022-00836-7"},{"key":"10.1016\/bs.irn.2026.01.002_bib66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clim.2016.09.010","article-title":"An emerging role for eotaxins in neurodegenerative disease","volume":"189","author":"Huber","year":"2018","journal-title":"Clinical Immunology (Orlando, Fla.)"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib68","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2026.01.002_bib69","doi-asserted-by":"crossref","unstructured":"Janelidze, S., et al. (2023b). Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. 2023b. 146(4), p. 1592\u20131601.","DOI":"10.1093\/brain\/awac333"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib70","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib71","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2026.01.002_bib72","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2026.01.002_bib73","unstructured":"Johnson, K. A., et al. (2013).\u00a0Appropriate use criteria for amyloid PET: A report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer\u2019s association. 9(1), p. E1-E16."},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13073-023-01155-w","article-title":"The neuroimmune axis of Alzheimer\u2019s disease","volume":"15","author":"Jorfi","year":"2023","journal-title":"Genome Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","article-title":"CSF p-tau increase in response to A\u03b2-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles","volume":"143","author":"Kaeser","year":"2022","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/bs.irn.2026.01.002_bib76","doi-asserted-by":"crossref","unstructured":"Karceski, S., &\u00a0Antonopoulos,\u00a0M. J. N. (2023).\u00a0Biomarkers in Alzheimer disease: A review. 101(4), p. e461-e463.","DOI":"10.1212\/WNL.0000000000207630"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib77","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2026.01.002_bib78","doi-asserted-by":"crossref","unstructured":"Karikari, T. K., et al.\u00a0(2021). Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s disease neuroimaging initiative. 26(2), p. 429\u2013442.","DOI":"10.1038\/s41380-020-00923-z"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tins.2017.01.002","article-title":"Mitophagy and Alzheimer\u2019s disease: Cellular and Molecular mechanisms","volume":"40","author":"Kerr","year":"2017","journal-title":"Trends in Neurosciences"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib80","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201197R","article-title":"Boosting of tau protein aggregation by CD40 and CD48 gene expression in Alzheimer\u2019s disease","volume":"37","author":"Kim","year":"2023","journal-title":"The FASEB Journal"},{"issue":"10","key":"10.1016\/bs.irn.2026.01.002_bib81","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.irn.2026.01.002_bib82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-2094-3-3","article-title":"CD40 deficiency mitigates Alzheimer\u2019s disease pathology in transgenic mouse models","volume":"3","author":"Laporte","year":"2006","journal-title":"Journal of Neuroinflammation"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib83","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00018-017-2664-0","article-title":"Amyloid precursor protein products concentrate in a subset of exosomes specifically endocytosed by neurons","volume":"75","author":"Laulagnier","year":"2018","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"9967","key":"10.1016\/bs.irn.2026.01.002_bib84","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/bs.irn.2026.01.002_bib85","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Molecular Psychiatry"},{"issue":"20","key":"10.1016\/bs.irn.2026.01.002_bib86","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1002\/elps.200406068","article-title":"Electrophoretic separation of amyloid beta peptides in plasma","volume":"25","author":"Lewczuk","year":"2004","journal-title":"Electrophoresis"},{"key":"10.1016\/bs.irn.2026.01.002_bib87","doi-asserted-by":"crossref","unstructured":"Li, R.-L., et al.\u00a0(2022a). Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases. 13\u20132022.","DOI":"10.3389\/fphar.2022.937289"},{"issue":"7","key":"10.1016\/bs.irn.2026.01.002_bib88","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","article-title":"Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib89","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood-brain barrier in health and disease","volume":"135","author":"Liebner","year":"2018","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/bs.irn.2026.01.002_bib90","doi-asserted-by":"crossref","unstructured":"Lista, S., et al.\u00a0(2016). Application of systems theory in longitudinal studies on the origin and progression of Alzheimer\u2019s disease. p. 49\u201367.","DOI":"10.1007\/978-1-4939-2627-5_2"},{"key":"10.1016\/bs.irn.2026.01.002_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.06.007","article-title":"Blood and plasma-based proteomic biomarker research in Alzheimer\u2019s disease","volume":"101-102","author":"Lista","year":"2013","journal-title":"Progress in Neurobiology"},{"issue":"12","key":"10.1016\/bs.irn.2026.01.002_bib92","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1007\/s12035-020-02073-3","article-title":"Gut microbiota and dysbiosis in Alzheimer\u2019s disease: Implications for pathogenesis and treatment","volume":"57","author":"Liu","year":"2020","journal-title":"Molecular Neurobiology"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib93","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neurobiolaging.2008.03.024","article-title":"Peripheral T cells derived from Alzheimer\u2019s disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent","volume":"31","author":"Liu","year":"2010","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/bs.irn.2026.01.002_bib94","doi-asserted-by":"crossref","unstructured":"Mamun, A. A., et al.\u00a0(2020). Toxic tau: Structural origins of tau aggregation in Alzheimer\u2019s disease. 15(8), p. 1417\u20131420.","DOI":"10.4103\/1673-5374.274329"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib95","article-title":"Identifying relevant outcomes in the progression of Alzheimer\u2019s disease; what do patients and care partners want to know about prognosis?","volume":"7","author":"Mank","year":"2021","journal-title":"Alzheimers Dement (NY)"},{"key":"10.1016\/bs.irn.2026.01.002_bib96","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren, N., et al.\u00a0(2020). Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. 11(1), p. 6252.","DOI":"10.1038\/s41467-020-19957-6"},{"issue":"6","key":"10.1016\/bs.irn.2026.01.002_bib97","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/bs.irn.2026.01.002_bib98","doi-asserted-by":"crossref","unstructured":"McGrowder, D. A., et al. (2021).\u00a0Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: Current evidence and future perspectives. 11(2), p. 215.","DOI":"10.3390\/brainsci11020215"},{"issue":"9","key":"10.1016\/bs.irn.2026.01.002_bib99","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2026.01.002_bib100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"9","key":"10.1016\/bs.irn.2026.01.002_bib101","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib102","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib103","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1084\/jem.20171406","article-title":"Alzheimer\u2019s disease: A matter of blood-brain barrier dysfunction?","volume":"214","author":"Montagne","year":"2017","journal-title":"The Journal of Experimental Medicine"},{"issue":"10","key":"10.1016\/bs.irn.2026.01.002_bib104","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1074\/jbc.M112.410944","article-title":"Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1","volume":"288","author":"Morel","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib105","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.1038\/s41598-017-08779-0","article-title":"Tau plasma levels in subjective cognitive decline: Results from the DELCODE study","volume":"7","author":"M\u00fcller","year":"2017","journal-title":"Scientific Reports"},{"issue":"7691","key":"10.1016\/bs.irn.2026.01.002_bib106","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib107","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/glia.20478","article-title":"Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia","volume":"55","author":"Nuttall","year":"2007","journal-title":"Glia"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","article-title":"Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic","volume":"13","author":"O\u2019Bryant","year":"2017","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"12","key":"10.1016\/bs.irn.2026.01.002_bib109","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/alz.12356","article-title":"Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer\u2019s disease","volume":"17","author":"Ossenkoppele","year":"2021","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib110","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib111","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA: the Journal of the American Medical Association"},{"issue":"8","key":"10.1016\/bs.irn.2026.01.002_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084115","article-title":"CD40-CD40L in neurological disease","volume":"23","author":"Ots","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/bs.irn.2026.01.002_bib113","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib114","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s13402-017-0335-7","article-title":"MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR\/HIF-1\u03b1\/VEGF signaling axis in breast cancer cells","volume":"40","author":"Pakravan","year":"2017","journal-title":"Cellular Oncology"},{"issue":"8","key":"10.1016\/bs.irn.2026.01.002_bib115","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA: the Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2026.01.002_bib116","doi-asserted-by":"crossref","unstructured":"Palmqvist, S., et al. (2021b). Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. 27(6), p. 1034\u20131042.","DOI":"10.1038\/s41591-021-01348-z"},{"issue":"6","key":"10.1016\/bs.irn.2026.01.002_bib117","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2026.01.002_bib118","doi-asserted-by":"crossref","unstructured":"Park, J. E., et al. (2022).\u00a0Diagnostic blood biomarkers in Alzheimer\u2019s disease. 10(1), p. 169.","DOI":"10.3390\/biomedicines10010169"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib119","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13910","article-title":"Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer\u2019s disease","volume":"53","author":"Pe\u00f1a-Bautista","year":"2023","journal-title":"European Journal of Clinical Investigation"},{"issue":"11","key":"10.1016\/bs.irn.2026.01.002_bib120","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib121","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.clinthera.2015.04.002","article-title":"Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation","volume":"37","author":"Petra","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib122","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.biopsych.2017.05.014","article-title":"Untangling genetic risk for Alzheimer\u2019s disease","volume":"83","author":"Pimenova","year":"2018","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010803.pub2","article-title":"CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)","author":"Ritchie","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"574","key":"10.1016\/bs.irn.2026.01.002_bib124","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc2888","article-title":"Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease","volume":"12","author":"Rodrigues","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.irn.2026.01.002_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2017.08.007","article-title":"APP\/A\u03b2 structural diversity and Alzheimer\u2019s disease pathogenesis","volume":"110","author":"Roher","year":"2017","journal-title":"Neurochemistry International"},{"issue":"5334","key":"10.1016\/bs.irn.2026.01.002_bib126","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1126\/science.277.5334.2005","article-title":"Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells","volume":"277","author":"Sallusto","year":"1997","journal-title":"Science (New York, N. Y.)"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib127","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Molecular Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib128","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuron.2018.04.035","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"98","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/bs.irn.2026.01.002_bib129","doi-asserted-by":"crossref","unstructured":"Shaw, L. M., et al.\u00a0(2018). Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease. 14(11), p. 1505\u20131521.","DOI":"10.1016\/j.jalz.2018.07.220"},{"key":"10.1016\/bs.irn.2026.01.002_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.576967","article-title":"CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis","volume":"333","author":"Shou","year":"2019","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2026.01.002_bib131","doi-asserted-by":"crossref","unstructured":"Simr\u00e9n, J., et al.\u00a0(2021). The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. 17(7), p. 1145\u20131156.","DOI":"10.1002\/alz.12283"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib132","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","article-title":"Correlation of In Vivo [18F]Flortaucipir with postmortem Alzheimer disease Tau pathology","volume":"76","author":"Smith","year":"2019","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2026.01.002_bib133","doi-asserted-by":"crossref","unstructured":"Smith, R., et al. (2023).\u00a0Tau\u2010PET is superior to phospho\u2010tau when predicting cognitive decline in symptomatic AD patients. 19(6), p. 2497\u20132507.","DOI":"10.1002\/alz.12875"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib134","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jalz.2013.10.007","article-title":"Developing novel blood-based biomarkers for Alzheimer\u2019s disease","volume":"10","author":"Snyder","year":"2014","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/bs.irn.2026.01.002_bib135","doi-asserted-by":"crossref","unstructured":"Soliman, H. M., et al. (2021).\u00a0Exosomes in Alzheimer\u2019s disease: From being pathological players to potential diagnostics and therapeutics. 22(19), p. 10794.","DOI":"10.3390\/ijms221910794"},{"key":"10.1016\/bs.irn.2026.01.002_bib136","doi-asserted-by":"crossref","unstructured":"Thambisetty, M. &\u00a0Bim,\u00a0S.J. (2010). Lovestone, blood-based biomarkers of Alzheimer\u2019s disease: Challenging but feasible. 4(1), p. 65\u201379.","DOI":"10.2217\/bmm.09.84"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib137","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated Tau biomarkers with amyloid positron emission tomography vs Tau positron emission tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2026.01.002_bib138","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib139","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","article-title":"Factors affecting A\u03b2 plasma levels and their utility as biomarkers in ADNI","volume":"122","author":"Toledo","year":"2011","journal-title":"Acta Neuropathologica"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11673-018-9844-y","article-title":"Review of the ethical issues of a biomarker-based diagnoses in the early stage of Alzheimer\u2019s disease","volume":"15","author":"Vanderschaeghe","year":"2018","journal-title":"Journal of Bioethical Inquiry"},{"issue":"4","key":"10.1016\/bs.irn.2026.01.002_bib141","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jalz.2013.03.007","article-title":"Designing drug trials for Alzheimer\u2019s disease: What we have learned from the release of the phase III antibody trials: A report from the EU\/US\/CTAD task force","volume":"9","author":"Vellas","year":"2013","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib142","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","article-title":"Combination of plasma amyloid beta(1-42\/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology","volume":"12","author":"Verberk","year":"2020","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib143","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","article-title":"Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: A prospective memory clinic-based cohort study","volume":"2","author":"Verberk","year":"2021","journal-title":"Lancet Healthy Longevity"},{"key":"10.1016\/bs.irn.2026.01.002_bib144","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpsychires.2019.10.002","article-title":"Increased ileal bile acid binding protein and galectin-9 are associated with mild cognitive impairment and Alzheimer\u2019s disease","volume":"119","author":"Wang","year":"2019","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/bs.irn.2026.01.002_bib145","doi-asserted-by":"crossref","unstructured":"West, T., et al.\u00a0(2021). A blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. 16(1), p. 30.","DOI":"10.1186\/s13024-021-00451-6"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib146","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40035-021-00270-1","article-title":"The role of pathological tau in synaptic dysfunction in Alzheimer\u2019s diseases","volume":"10","author":"Wu","year":"2021","journal-title":"Translational Neurodegeneration"},{"issue":"6","key":"10.1016\/bs.irn.2026.01.002_bib147","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.14336\/AD.2022.0412","article-title":"Amyloid cascade hypothesis for the treatment of Alzheimer\u2019s disease: Progress and challenges","volume":"13","author":"Wu","year":"2022","journal-title":"Aging and Disease"},{"issue":"2","key":"10.1016\/bs.irn.2026.01.002_bib148","doi-asserted-by":"crossref","first-page":"C135","DOI":"10.1152\/ajpcell.00136.2018","article-title":"Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke","volume":"316","author":"Yang","year":"2019","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib149","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1878-5085-4-23","article-title":"From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine","volume":"4","author":"Younesi","year":"2013","journal-title":"EPMA Journal"},{"issue":"9","key":"10.1016\/bs.irn.2026.01.002_bib150","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between A\u03b2 and Tau in the pathogenesis of Alzheimer\u2019s disease","volume":"17","author":"Zhang","year":"2021","journal-title":"International Journal of Biological Sciences"},{"key":"10.1016\/bs.irn.2026.01.002_bib151","doi-asserted-by":"crossref","unstructured":"Zhang, H., et al.\u00a0(2022). The trajectory of cerebrospinal fluid growth-associated protein 43 in the Alzheimer\u2019s disease continuum: A longitudinal study. 85(4), p. 1441\u20131452.","DOI":"10.3233\/JAD-215456"},{"issue":"1","key":"10.1016\/bs.irn.2026.01.002_bib152","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1038\/s41467-023-42505-x","article-title":"Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer\u2019s disease","volume":"14","author":"Zhang","year":"2023","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/bs.irn.2026.01.002_bib153","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","article-title":"Establishment and dysfunction of the blood-brain barrier","volume":"163","author":"Zhao","year":"2015","journal-title":"Cell"},{"key":"10.1016\/bs.irn.2026.01.002_bib154","doi-asserted-by":"crossref","unstructured":"Zhou, B., et al.\u00a0(2022). Synaptogenic effect of APP-Swedish mutation in familial Alzheimer\u2019s disease. 14(667), p. eabn9380.","DOI":"10.1126\/scitranslmed.abn9380"},{"issue":"7","key":"10.1016\/bs.irn.2026.01.002_bib155","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.neurobiolaging.2006.05.016","article-title":"Microvascular injury and blood-brain barrier leakage in Alzheimer\u2019s disease","volume":"28","author":"Zipser","year":"2007","journal-title":"Neurobiology of Aging"}],"container-title":["International Review of Neurobiology","Blood-Based Biomarkers for Alzheimers and Parkinsons Disease - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774226000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774226000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:07Z","timestamp":1790267047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774226000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443472169"],"references-count":155,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2026.01.002","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}